CSI Market
Sign In | Register

Acumen Pharmaceuticals Inc (ABOS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ABOS quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Acumen Pharmaceuticals Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-121.34
Depreciation & amortization0.06
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation9.85
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Fair Value Adjustment Of Preferred Stock Tranche Rights Liability And Preferred Stock Warrant Liability-
Operating Lease Right Of Use Asset Amortization Expense0.13
Other Noncash Expense Interest1.29
Increase Decrease In Finance Lease Liability-
Increase Decrease In Accrued Clinical Trial Expenses-4.73
Income taxes0.00
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total-0.06
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-5.09
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities3.30
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.36
Other Working Capital0.04
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.35
Discontinued operations0.00
Net Cash flow from Operating Activities-115.54
Investing Activities
Capital Expenditures-0.09
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities172.08
Payments to Acquire Marketable Securities-38.06
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities133.93
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.04
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-35.93
Payments For Deferred Offering Costs-
Reclassification Of Preferred Stock Tranche Rights Liability Upon Share Issuance-
Reclassification Of Warrant Liability Upon Exercise Of Preferred Stock Warrant-
Deferred Offering Costs In Accounts Payable-
Deferred Offering Costs In Accrued Expenses And Other Current Liabilities-
Proceeds From Issuance Of Mile Stone Shares Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents35.86
Proceeds From Warrant Exercises Convertible Preferred Stock-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-115.63
Total Cash Flow18.36
4 historic quarters locked

Sign in to unlock the full Acumen Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Acumen Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-021413

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document